CA2819554A1 - Dosage and administration of bispecific scfv conjugates - Google Patents
Dosage and administration of bispecific scfv conjugates Download PDFInfo
- Publication number
- CA2819554A1 CA2819554A1 CA2819554A CA2819554A CA2819554A1 CA 2819554 A1 CA2819554 A1 CA 2819554A1 CA 2819554 A CA2819554 A CA 2819554A CA 2819554 A CA2819554 A CA 2819554A CA 2819554 A1 CA2819554 A1 CA 2819554A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- composition
- intervals
- days
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42199210P | 2010-12-10 | 2010-12-10 | |
| US61/421,992 | 2010-12-10 | ||
| PCT/US2011/064496 WO2012079093A2 (en) | 2010-12-10 | 2011-12-12 | Dosage and administration of bispecific scfv conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2819554A1 true CA2819554A1 (en) | 2012-06-14 |
Family
ID=46207797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2819554A Abandoned CA2819554A1 (en) | 2010-12-10 | 2011-12-12 | Dosage and administration of bispecific scfv conjugates |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140017264A1 (https=) |
| EP (1) | EP2648753A4 (https=) |
| JP (1) | JP2014500278A (https=) |
| AU (1) | AU2011341337A1 (https=) |
| CA (1) | CA2819554A1 (https=) |
| WO (1) | WO2012079093A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| EP2566892B1 (en) | 2010-05-06 | 2017-12-20 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
| PH12012502193A1 (en) | 2010-05-06 | 2021-08-09 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| CN103547598A (zh) * | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
| ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| MX2014013763A (es) * | 2012-05-11 | 2015-02-20 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2016022723A1 (en) | 2014-08-05 | 2016-02-11 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| MX2010011145A (es) * | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
-
2011
- 2011-12-12 EP EP11847515.1A patent/EP2648753A4/en not_active Withdrawn
- 2011-12-12 CA CA2819554A patent/CA2819554A1/en not_active Abandoned
- 2011-12-12 JP JP2013543410A patent/JP2014500278A/ja not_active Withdrawn
- 2011-12-12 US US13/992,460 patent/US20140017264A1/en not_active Abandoned
- 2011-12-12 AU AU2011341337A patent/AU2011341337A1/en not_active Abandoned
- 2011-12-12 WO PCT/US2011/064496 patent/WO2012079093A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012079093A2 (en) | 2012-06-14 |
| EP2648753A2 (en) | 2013-10-16 |
| AU2011341337A1 (en) | 2013-06-13 |
| EP2648753A4 (en) | 2015-06-24 |
| US20140017264A1 (en) | 2014-01-16 |
| JP2014500278A (ja) | 2014-01-09 |
| WO2012079093A3 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140017264A1 (en) | Dosage and administration of bispecific scfv conjugates | |
| US7794713B2 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2004527456A (ja) | Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療 | |
| TW201834687A (zh) | 抗-cd19類美登醇(maytansinoid )免疫結合物抗體於治療b-細胞惡性症狀之用途 | |
| EP3042669A1 (en) | Antitumor agent and antitumor effect enhancer | |
| JP6488273B2 (ja) | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 | |
| JP6722688B2 (ja) | 医薬組成物、調製及びその使用 | |
| US20050112061A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| CN118806923A (zh) | 西妥昔单抗-ir700偶联物组合物 | |
| JP2023549464A (ja) | Ｂ細胞免疫寛容の誘導及びｍＩｇＭ陽性発現Ｂ細胞リンパ腫の標的化における葉酸及び葉酸修飾の使用 | |
| US20230001006A1 (en) | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers | |
| AU2005325227B2 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
| WO2019238713A2 (en) | Treatments etc | |
| US20200093789A1 (en) | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor | |
| CN119255817A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| US20250381268A1 (en) | Pharmaceutical composition comprising anti-ctla4 and anti-pd1 antibody mixture and therapeutic use thereof | |
| WO2023160517A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| Huang et al. | Dual‐Functional Sonodynamic Therapeutic Platform for Complete Osteosarcoma Elimination With Synchronized Bone Defect Regeneration | |
| CN119300862A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| KR20210106197A (ko) | EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발 | |
| CN118946366A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| JP2024037356A (ja) | 医薬 | |
| KR20260042531A (ko) | Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20161214 |